anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic subdural hematoma (CSDH) development involves inflammatory, angiogenetic, and fibrinolytic mechanisms, several components of which are now unraveled through intensive research. The urokinase plasminogen activator receptor (uPAR) is part of the plasminogen activator system and possesses inflammatory, angiogenetic, and fibrinolytic capabilities. As a first, this study aims to identify uPAR in the hematoma fluid, hematoma membrane, dura mater, and systemic blood from patients with CSDH and, if present, to investigate if the uPAR level at the time of surgery may be a predictor for later developing recurrent CSDH. uPAR expression in the hematoma membrane and dura mater was analyzed using immunohistochemistry and presented as the H-score of the positive immunostaining. The uPAR levels in the hematoma fluid and systemic blood were determined using a multiplex antibody bead kit (Luminex). Samples were collected at the time of the first CSDH surgery, and in the case of recurrent CSDH within 90 days, the samples were again collected at reoperation. A comparison of uPAR expression between the hematoma membrane and dura mater, as well as uPAR levels in systemic blood and hematoma fluid, was performed using the Wilcoxon rank sum test. We included 112 patients, 26 of whom had recurrent CSDH. The median hematoma uPAR level was 22,125 (14,845-33,237) and significantly higher than the median systemic blood level of 789 pg/L (465-2,088) (p < 0.001). Similarly, the uPAR level of the hematoma membrane was 14.3 (7.54-44.8) and significantly higher than the dural uPAR level of 0.81 (0.3-1.98) (p < 0.001). For the first time, we identified uPAR in the subdural fluid, hematoma membrane, dura mater, and systemic blood from patients with CSDH. The high expression of uPAR in the subdural fluid and hematoma membrane indicates that the mechanisms of CSDH are predominantly in the subdural fluid collection and surrounding hematoma membrane.
The influence of endophytic microbial community on plant growth and disease resistance is of considerable importance. Prior research indicates that pre-treatment of kiwifruit with the biocontrol yeast Debaryomyces hansenii suppresses gray mold disease induced by Botrytis cinerea. However, the specific underlying mechanisms remain unclear. In this study, Metagenomic sequencing was utilized to analyze the composition of the endophytic microbiome of kiwifruit under three distinct conditions: the healthy state, kiwifruit inoculated with B. cinerea, and kiwifruit treated with D. hansenii prior to inoculation with B. cinerea. Results revealed a dominance of Proteobacteria in all treatment groups, accompanied by a notable increase in the relative abundance of Actinobacteria and Firmicutes. Ascomycota emerged as the major dominant group within the fungal community. Treatment with D. hansenii induced significant alterations in microbial community diversity, specifically enhancing the relative abundance of yeast and exerting an inhibitory effect on B. cinerea. The introduction of D. hansenii also enriched genes associated with energy metabolism and signal transduction, positively influencing the overall structure and function of the microbial community. Our findings highlight the potential of D. hansenii to modulate microbial dynamics, inhibit pathogenic organisms, and positively influence functional attributes of the microbial community.
The invention discloses rhodiola crenulata body lotion with whitening and nourishing effects. The rhodiola crenulata body lotion is mainly prepared from rhodiola crenulata root extract, blueberry fruit extract, black tea extract, palmarosa oil and corresponding adjuvants. Rhodiola crenulata can nourish and moisturize skin and keep constant moisture and elasticity of the skin, has anti-oxidation and whitening functions and is called 'gold plant' in the Compendium of Materia Medica. Blueberry is rich in anthocyanin which is a purely natural anti-aging nutrition supplement. Black tea can moisturize skin, promote blood circulation and activate cells, and also has antibacterial and refreshing functions and the like. Palmarosa can restore the skin to a moisture state, adjust sebum excretion and promote cell regeneration and the pleasant aroma of the palmarosa has mood-soothing and refreshing effects. The rhodiola crenulata body lotion, taking rhodiola crenulata as 'monarch', blueberry as 'minister', black tea as 'assistant' and palmarosa as 'guide', can effectively remove free radicals, build a defensive line for the skin and moisturize, nourishe and naturally whiten the skin.
A system (Fig. 1) and method of detecting of insurance premium fraud due to the misrepresentation of policy related information by the policyholder is provided by a predictive model (Fig. 2), which uses peer group policy data (205), historical variables (203), and internal variables (207) to assess the likelihood of premium fraud for each policy. The predictive model (Fig. 2) produces a score (410) for the policy, which is a measure of the likelihood of a misrepresentation of policy information. The score is then ranked, and the policy is audited to confirm premium fraud or abuse.
As known to all, the dosage and duration of glucocorticoid influences the glucose levels in different diseases. Continuous glucose monitoring becomes a newly effective technology to better understand the glucose level. In this study,the investigators enrolled 25 patients with certain active autoimmune diseases during high-dosage glucocorticoid therapy at Peking Union Medical College Hospital. It was done by monitoring three-day continuous glucose levels by holding continuous glucose monitoring system underneath the skin, which helped to show a unique picture of fluctuations. The participants were divided into two groups according to the glucocorticoid therapy. Group 1 enrolled subjects who were newly commenced 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) for at least five days. Group 2 enrolled subjects who had underwent less than 15mg/day prednisone-equivalent glucocorticoid maintenance for at least 3 months but treated with high-dose glucocorticoid for the relapse during the study This finding is useful for the suitable treatment to control the hyperglycemia in young patients.
Acitretin and other retinoids administered orally have been associated with cases of pseudotumor cerebri (benign intracranial hypertension). Some of these events involved concomitant use of isotretinoin and tetracyclines. However, the event seen in a single patient receiving acitretin was not associated with tetracycline use. Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances. Patients with these signs and symptoms should be examined for papilledema and, if present, should discontinue acitretin immediately and be referred for neurological evaluation and care. Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated (see CONTRAINDICATIONS).
A compound which has at least two phosphor parts and a structure represented by general formula (I), and a labeled biomaterial.　In the formula, X1 to X3 represent -O-, -S-, >NR1 or >CR2R3. R1 to R3 represent a hydrogen atom or a substituent. La and Lb represent a single bond or a divalent linking group. n is an integer greater than or equal to 2.　However, at least one of R1 to R3, La and Lb which are included in the structure enclosed in ( )n includes -(L-O)gRE, and -(L-O)gRE in these groups is not bonded to at least one of a phosphor and a biomaterial.　L represents an alkylene group, RE represents a hydrogen atom or an alkyl group, and g is 1 to 24.　* represents an atomic bond.
It is particularly important to administer bupropion hydrochloride tablets in a manner most likely to minimize the risk of seizure (see WARNINGS). Increases in dose should not exceed 100 mg/day in a 3 day period. Gradual escalation in dosage is also important if agitation, motor restlessness, and insomnia, often seen during the initial days of treatment, are to be minimized. If necessary, these effects may be managed by temporary reduction of dose or the short-term administration of an intermediate to long-acting sedative hypnotic. A sedative hypnotic usually is not required beyond the first week of treatment. Insomnia may also be minimized by avoiding bedtime doses. If distressing, untoward effects supervene, dose escalation should be stopped.

No single dose of bupropion hydrochloride tablets should exceed 150 mg. Bupropion hydrochloride tablets should be administered 3 times daily, preferably with at least 6 hours between successive doses.
This study explores the anti-inflammatory effects of non-cyclic nucleotide EPAC1 activators, PW0577 and SY007, on lipopolysaccharide (LPS)-induced responses in differentiated THP-1 macrophage-like cells. Both activators were found to selectively activate EPAC1 in THP-1 macrophages, leading to the activation of the key down-stream effector, Rap1. RNA sequencing analysis of LPS-stimulated THP-1 macrophages, revealed that treatment with PW0577 or SY007 significantly modulates gene expression related to fibrosis and inflammation, including the suppression of NLRP3, IL-1β, and caspase 1 protein expression in LPS-stimulated cells. Notably, these effects were independent of p65 NFκB phosphorylation at Serine 536, indicating a distinct mechanism of action. The study further identified a shared influence of both activators on LPS signalling pathways, particularly impacting extracellular matrix (ECM) components and NFκB-regulated genes. Additionally, in a co-culture model involving THP-1 macrophages, vascular smooth muscle cells, and human coronary artery endothelial cells, EPAC1 activators modulated immune-vascular interactions, suggesting a broader role in regulating cellular communication between macrophages and endothelial cells. These findings enhance our understanding of EPAC1's role in inflammation and propose EPAC1 activators as potential therapeutic agents for treating inflammatory and fibrotic conditions through targeted modulation of Rap1 and associated signalling pathways.
This was the only arm in the study. All participants were allocated to this arm, where they received an 8-week remotely-delivered exercise and nutrition program.
The present invention comprises an agent exhibiting an antiarrhythmic effect, extracted from plants of genus  Aconitum  family Ranunculaceae, containing the alkaloids lappaconitine, N-acetylsepaconitine, 1-desmethyllappaconitine, ranaconitine, N-deacetyllappaconitine, isolappaconitine, 9-deoxy-lappaconitine or pharmaceutically acceptable salts thereof. The agent contains alkaloids in the form of hydrobromide salts of lappaconitine, N-acetylsepaconitine, 1-desmethyllappaconitine, ranaconitine, N-deacetyllappaconitine, isolappaconitine, and 9-deoxy-lappaconitine. In specific implementations, the agent may be extracted from the rhizomes and roots of the plant  Aconitum septentrionale Koelle , from the rhizomes and roots of the plant  Aconitum leucostomum , or from the herb of the plant  Aconitum leucostomum , all of the family Ranunculaceae. A pharmaceutical composition for oral administration comprises the agent in an effective quantity and a pharmaceutically acceptable carrier. Preferably, the pharmaceutically acceptable carrier contains starch, sucrose, calcium stearate, and croscarmellose sodium. The present invention provides a more effective and safe cardioprotective agent for the prevention and treatment of arrhythmia.
OBJECTIVE: Activation of gap junction channels can induce neuropathic pain. Octanol can limit the conductance of gap junctions containing connexin 43 proteins. Thus, this study focused on the roles of octanol in chronic constriction injury (CCI)-induced peripheral neuropathy in mice and its mechanisms of action.
METHODS: Male mice were assigned into control, sham, CCI, CCI + Octanol-20 mg/kg, CCI + Octanol-40 mg/kg and CCI + Octanol-80 mg/kg groups. CCI was performed by applying three loose ligations to mouse sciatic nerve, and the mice with CCI was administered with 20 mg/kg, 40 mg/kg, or 80 mg/kg octanol. The neuropathic pain development was examined by assessing thermal withdrawal latency, paw withdrawal mechanical threshold, and sciatic functional index. Histopathological changes were evaluated by hematoxylin and eosin staining. The phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR) was examined by western blotting. The expression of Akt and mTOR was also evaluated by immunofluorescence staining.
RESULTS: Octanol alleviated the CCI-induced mechanical and thermal hyperalgesia and sciatic functional loss. Additionally, octanol relieved the CCI-induced abnormal histopathological changes. Mechanistically, octanol inactivated the Akt/mTOR pathway in the mice with CCI.
CONCLUSION: In conclusion, octanol can alleviate CCI-induced peripheral neuropathic by regulating the Akt/mTOR pathway and might be a novel pharmacological intervention for neuropathic pain.
PROBLEM TO BE SOLVED: To obtain a bath or pack preparation easily usable for e.g. health promotion, beauty culture even at general home by compounding a granular water-insoluble, water-swellable resin with a hydrophilic powder or aqueous solution containing medicinal and/or fragrant ingredient(s). SOLUTION: This preparation is obtained by compounding (A) a granular water-insoluble, water-swellable resin having an average particle diameter of, pref., 50-800 μm and a water absorption performance for pure water of >=50-fold, e.g. water-insoluble water-swellable resin derived from polysaccharides (e.g. partially neutralized crosslinked product derived from starch-acrylic acid graft polymer and a crosslinked polymer of a radical-polymerizable monomer (e.g. a polysulfonic acid salt crosslinked product) and (B) a hydrophilic powder or an aqueous solution having a particle diameter of pref. 10-2000 μm and containing medicinal and/or fragrant ingredient(s). It is preferable that the compounding ratio of the above medicinal and/or fragrant ingredient(s) is 0.1-50 wt.%, based on the total weight of the medicinal and/or fragrant ingredient(s) in the above component B and the component A.
Though unified by challenges in the treatment of status epilepticus (SE), rural Canada is simultaneously massive and diverse, spanning the Pacific, Atlantic, and Arctic Oceans. According to the national statistical agency, the most rural jurisdiction in Canada is the Arctic territory of Nunavut. In particular, the Kivalliq region of Nunavut represents a unique epidemiologic SE space because any treatment beyond typical first-line lorazepam and second-line phenytoin by a non-neurologist locum tenens requires airborne evacuation over a thousand kilometers away to a single hospital with a single electroencephalographic (EEG) laboratory. This distinctive mode of healthcare delivery affords unique insights into the challenges of treating SE in rural Canada, such as lack of EEG infrastructure, a markedly high incidence of SE, the struggles of enduring cultural and socioeconomic trauma, and a relative lack of local epilepsy care as recommended by the World Health Organization. For example, despite empiric treatment and waiting over 2 days on average for EEG, 1 in 5 patients still had ongoing or possible electrographic seizures. At the same time, Kivalliq experiences routine dramatic changes in light-dark exposure each year to afford unique insights into circannual SE chronobiology in relation to the chief human zeitgeber of sunlight. This shows that challenges may also represent opportunities, such as for existing and emerging technologies to synergistically address enormous treatment gaps to improve SE care for the people of Kivalliq, while providing novel insights that may also help improve SE clinical care around the world.
The intervention applied to the experimental group will consist of 20 sessions of conventional OT distributed in two sessions per week, each lasting 30 minutes. Additionally, they will receive 20 treatment sessions lasting 20 minutes, twice weekly of virtual reality (VR) via the online and free website motiongamingconsole.com, during which they will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro. All the interventions will consider the level of fatigue experimented by the patient by featuring a progressive increase of the treatment times according to the same.
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 4 cycles (24 weeks).
PURPOSE: To treat an immune disorder, inflammation and chromic infectious disease by dosing an effective amt. of a compsn. contg. intracellular glutathione stimulants and ω-3 fatty acid sources to a patient. CONSTITUTION: A virus infectious disease and immune disorder are treated by dosing the compsn. which contains (A) the intracellular glutathione stimulants; for example, glutathione, L-2-oxothiazolidine-4-carboxylate, glutathione esters, compsn. rich in cysteine, N-acetyl cysteine and (B) the ω-3 fatty acid sources, more preferably the marine product oils selected from menhaden oil, mackerel oil, alga oil, herring oil, horse mackerel oil, anchovy oil and salmon oil at a ratio of A to B of 0.05 to 1.25 and in which A constitutes at least 0.15% of the total calorie and B at least 1.5% of the total calorie to the patient.
The inventive pharmaceutical composition having thrombolytic anti-inflammatory and cytoprotective properties comprises active proteases attached to a gel or the mixture of gel and a water-soluble polymer. Said attachment is carried out with the aid of radiation, preferably gamma-radiation or accelerated electrons. Said composition also contains proteases which are stable at a temperature up to 70 °C, preferably at a temperature ranging from 30 to 40 °C, such as subtilisin, chymotripsin, papayotin or streptokinase. Polyethylene, dextrane or polyglicane gels are preferably used as a gel. The water-soluble polymer is embodied in the form of polyethylenglicol, polyvinyl alcohol, dextrane or polyglycan. The method for producing and using said composition is also disclosed. The inventive composition can be widely used for cardiology, nephrology, surgery rheumatology, gynecology and gastroenterology.
Patients with MINOCA and an index of microvascular resistance (IMR) greater than or equal to 25 will be randomised to receive eplerenone (starting dose 25 mg, uptitrated to 50 mg after two weeks) for six months or standard of care and research protocol study visits. Patients who are screened, give informed consent but are not randomized will enter a followup registry.
The hypometabolic and nutrient-limiting condition of dormant bacteria inside biofilms reduces their susceptibility to antibacterial agents, making the treatment of biofilm-dominating chronic infections difficult. Herein, we demonstrate an intratracheal aerosolized maltohexaose-modified catalase-gallium integrated nanosystem that can 'wake up' dormant Pseudomonas aeruginosa biofilm to increase the metabolism and nutritional iron demand by reconciling the oxygen gradient. The activated bacteria then enhance suicidal gallium uptake since gallium acts as a 'Trojan horse' to mimic iron. The internalized gallium ions disrupt biofilms by interfering with the physiological processes of iron ion acquisition and utilization, biofilm formation, and quorum sensing. Furthermore, aerosol microsprayer administration and bacteria-specific maltohexaose modification enable accumulation at biofilm-infected lung and targeted release of gallium into bacteria to improve the therapeutic effect. This work provides a potential strategy for treating infection by reversing the dormant biofilm's resistance condition.
BACKGROUND AND AIM: The present study aimed to analyze the correlation between carotid atherosclerotic plaque (CAP) and/or subclavian atherosclerotic plaque (SAP) and coronary atherosclerosis disease (CASD).
METHODS: A total of 1343 patients hospitalized for chest pain or tightness due to coronary atherosclerotic disease and underwent initial coronary angiography (CAG) were evaluated by color Doppler flow imaging (CDFI) for CAP and SAP. The patients were divided into four groups: non-CAP & non-SAP, only-SAP, only-CAP, or CAP & SAP. Finally, 1,242 patients were included in this study.
RESULTS: The incidence of CASD and main coronary artery disease in the CAP & SAP group was higher than that in the CAP-only group. Moreover, the detection rate of three-vessel disease (3-VD) in the CAP & SAP group was significantly higher than that in the CAP group (p < 0.05). The incidence of main coronary artery branch lesions in patients with CAP & SAP was approximately 1.5 times higher than in those with only CAP. Male gender, hypertension, and diabetes were independent risk factors for main coronary artery branch lesions. If the patient had CAP & SAP lesions and more than three cardiovascular disease risk factors, coronary artery main artery disease incidence was about 81.7% CONCLUSION: Based on the CDFI screening and combined with cardiovascular disease risk factors, the combined evaluation of CAP and SAP showed higher CASD prediction values than the CAP group alone. Early detection of coronary atherosclerotic stenosis and timely clinical intervention is expected to reduce the incidence of ischemic heart disease events caused by coronary atherosclerotic stenosis.
PURPOSE: To obtain a hair tonic having excellent hair-nourishing activity to various alopecia independent of symptom or individual difference by including a glyceryl etherified polyhydric alcohol. CONSTITUTION: This hair tonic contains a compound expressed by formula I (R<1> is a 6-22C alkyl, an alkenyl or an alkoxyalkyl; R<2> is H or expressed by formula II) in an amount of 0.0001-20wt.%, preferably 0.01-10wt.% as an active component. Otherwise, the hair tonic may be jointly used with a hematogenic accelerator, an antibacterial agent, a cuticle-dissolving agent, an anti-seborrhea agent, a local stimulating agent, an anti-inflammatory agent, a humectant, an anti-androgenic hormone agent or a hair follicle activator, etc., in an amount of 0.001-5wt.% for enhancing the hair-nourishing effect. Furthermore, the objective cosmetic is suitably mixed with an additive used in an usual cosmetic and mainly prepared in a formulation of lotion. A formulation of cream or gel is also possible. A liquid agent is preferably mixed with a carbon dioxide gas and adjusted to pH4.5-6.5.
Systems and techniques for adjusting experiment parameters are illustrated. One embodiment includes a method that defines a joint distribution, wherein the joint distribution corresponds to a combination of a probabilistic model and a point prediction model, and wherein the point prediction model is configured to obtain a measurement of regression accuracy. The method derives an energy function for the joint distribution. The method obtains, from the energy function for the joint distribution, an approximation for a conditional distribution, wherein an output of the point prediction model is a parameter of the approximation. The method determines, from a loss function, at least one training parameter. The method trains the probabilistic based on the at least one parameter to operate as a conditional generative model, wherein the trained probabilistic model follows the conditional distribution. The method applies the trained probabilistic model to a dataset corresponding to a randomized trial.